K Koehler1, D Liebner2, J L Chen3. 1. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus. 2. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus Division of Bioinformatics, Department of Biomedical Informatics, The Ohio State University, Columbus, USA. 3. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus Division of Bioinformatics, Department of Biomedical Informatics, The Ohio State University, Columbus, USA james.chen@osumc.edu.
Abstract
BACKGROUND: To investigate whether TP53 DNA mutational status impacts progression-free survival (PFS) in patients with advanced sarcomas (soft tissue sarcoma) treated with vascular endothelial growth factor receptors (VEGFR) inhibition. PATIENTS AND METHODS: We retrospectively reviewed 19 cases of patients treated at the Ohio State James Comprehensive Cancer Center with advanced sarcoma treated with VEGFR inhibition who also had next-generation sequencing of their tumors (via FoundationOne Heme panel). We evaluated TP53 as well as mutations that were observed in at least 20% of patients and evaluated its contribution to PFS using the Kaplan-Meier survival analysis of available radiology end points. RESULTS: Mutations that were observed in at least 20% of patients included TP53 and Rb1. Only TP53 was predictive of PFS in the context of VEGFR inhibition. The PFS of patients with TP53 mutations was significantly greater than TP53 wild-type tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)]. CONCLUSIONS: Mutations in TP53 may serve as a predictive biomarker of response to VEGFR inhibition in patients with advanced sarcoma. Larger, prospective studies are necessary to confirm these findings.
BACKGROUND: To investigate whether TP53 DNA mutational status impacts progression-free survival (PFS) in patients with advanced sarcomas (soft tissue sarcoma) treated with vascular endothelial growth factor receptors (VEGFR) inhibition. PATIENTS AND METHODS: We retrospectively reviewed 19 cases of patients treated at the Ohio State James Comprehensive Cancer Center with advanced sarcoma treated with VEGFR inhibition who also had next-generation sequencing of their tumors (via FoundationOne Heme panel). We evaluated TP53 as well as mutations that were observed in at least 20% of patients and evaluated its contribution to PFS using the Kaplan-Meier survival analysis of available radiology end points. RESULTS: Mutations that were observed in at least 20% of patients included TP53 and Rb1. Only TP53 was predictive of PFS in the context of VEGFR inhibition. The PFS of patients with TP53 mutations was significantly greater than TP53 wild-type tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)]. CONCLUSIONS: Mutations in TP53 may serve as a predictive biomarker of response to VEGFR inhibition in patients with advanced sarcoma. Larger, prospective studies are necessary to confirm these findings.
Authors: Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger Journal: Lancet Date: 2012-05-16 Impact factor: 79.321
Authors: S Fu; M M Hou; A Naing; F Janku; K Hess; R Zinner; V Subbiah; D Hong; J Wheler; S Piha-Paul; A Tsimberidou; D Karp; D Araujo; B Kee; P Hwu; R Wolff; R Kurzrock; F Meric-Bernstam Journal: Ann Oncol Date: 2015-02-10 Impact factor: 32.976
Authors: B Kasper; S Sleijfer; S Litière; S Marreaud; J Verweij; R A Hodge; S Bauer; J M Kerst; W T A van der Graaf Journal: Ann Oncol Date: 2014-02-06 Impact factor: 32.976
Authors: M Farhang Ghahremani; S Goossens; D Nittner; X Bisteau; S Bartunkova; A Zwolinska; P Hulpiau; K Haigh; L Haenebalcke; B Drogat; A Jochemsen; P P Roger; J-C Marine; J J Haigh Journal: Cell Death Differ Date: 2013-03-01 Impact factor: 15.828
Authors: Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell Journal: Nucleic Acids Res Date: 2014-10-29 Impact factor: 16.971
Authors: Apostolia-Maria Tsimberidou; David S Hong; Yang Ye; Carrie Cartwright; Jennifer J Wheler; Gerald S Falchook; Aung Naing; Siqing Fu; Sarina Piha-Paul; Filip Janku; Funda Meric-Bernstam; Patrick Hwu; Bryan Kee; Merrill S Kies; Russell Broaddus; John Mendelsohn; Kenneth R Hess; Razelle Kurzrock Journal: JCO Precis Oncol Date: 2017-09-08
Authors: Shumei Kato; Nithya Krishnamurthy; Kimberly C Banks; Pradip De; Kirstin Williams; Casey Williams; Brian Leyland-Jones; Scott M Lippman; Richard B Lanman; Razelle Kurzrock Journal: Cancer Res Date: 2017-06-22 Impact factor: 12.701
Authors: Ahmed O Kaseb; Nora S Sánchez; Shiraj Sen; Robin K Kelley; Benjamin Tan; Andrea G Bocobo; Kian H Lim; Reham Abdel-Wahab; Marc Uemura; Roberto Carmagnani Pestana; Wei Qiao; Lianchun Xiao; Jeffrey Morris; Hesham M Amin; Manal M Hassan; Asif Rashid; Kimberly C Banks; Richard B Lanman; AmirAli Talasaz; Kenna R Mills-Shaw; Bhawana George; Abedul Haque; Kanwal P S Raghav; Robert A Wolff; James C Yao; Funda Meric-Bernstam; Sadakatsu Ikeda; Razelle Kurzrock Journal: Clin Cancer Res Date: 2019-07-30 Impact factor: 13.801
Authors: Aaron M Goodman; Shumei Kato; Philip R Cohen; Amélie Boichard; Garrett Frampton; Vincent Miller; Philip J Stephens; Gregory A Daniels; Razelle Kurzrock Journal: Oncoimmunology Date: 2017-12-22 Impact factor: 8.110
Authors: Jianwen Hao; Qizhen Peng; Keruo Wang; Ge Yu; Yi Pan; Xiaoling Du; Na Hu; Xuening Zhang; Yu Qin; Huikai Li Journal: Biomed Res Int Date: 2021-07-22 Impact factor: 3.411